公开(公告)号：US20210054061A1

公开(公告)日：2021-02-25

申请号：US17050384

申请日：2019-04-15

申请人： NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY ,  NIIGATA UNIVERSITY ,  NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY ,  KAWASAKI GAKUENN EDUCATIONAL FOUNDATION

发明人： Masakiyo SAKAGUCHI ,  Shinichi TOYOOKA ,  Shuta TOMIDA ,  Kazuhiko SHIEN ,  Hiroki SATO ,  Rie KINOSHITA ,  Junichiro FUTAMI ,  Kota ARAKI ,  Mikio OKAZAKI ,  Eisaku KONDO ,  Yusuke INOUE ,  Akira YAMAUCHI

IPC分类号： C07K16/24 ,  A61P35/04 ,  A61P11/00

摘要： Provided is a substance capable of effectively suppressing cancer metastasis or a pharmaceutical composition that effectively acts on an inflammatory disease. The pharmaceutical composition is a pharmaceutical composition containing, as an active ingredient, an antibody or an antibody fragment thereof having antigen-binding activity for an S100A8/A9 heterodimer, and blocks interaction between S100A8/A9 and a group of receptors therefor, to thereby strongly suppress cancer metastasis both in vitro and in vivo, or alleviate inflammation. That is, the anti-S100A8/A9 antibody or the antibody fragment thereof can strongly suppress cancer metastasis or alleviate inflammation, by virtue of its blocking action on the interaction between S100A8/A9 and the group of receptors therefor.

公开(公告)号：US20220175940A1

公开(公告)日：2022-06-09

申请号：US17593570

申请日：2020-02-27

申请人： NIIGATA UNIVERSITY

发明人： Eisaku KONDO

IPC分类号： A61K47/64 ,  C07K7/06 ,  A61K47/36 ,  A61K47/42 ,  A61P35/00

摘要： A peptide is composed of an amino acid sequence represented by general formula (I), and accumulates in cancer-associated fibroblasts. (In general formula (I), X11 is a peptide residue composed of an amino acid sequence of (a) or (b) below: (a) an amino acid sequence represented by any one of SEQ ID NOs: 1 to 4, (b) an amino acid sequence in which one or two amino acids have been deleted, substituted or added in an amino acid sequence represented by any one of SEQ ID NOs: 1 to 4; Y11 is a peptide linker composed of an amino acid residue of at least 1 but not more than 10 amino acids, wherein each amino acid residue is independently a glycine residue, a proline residue, a serine residue, a cysteine residue or a lysine residue; X12 is either a peptide residue composed of an amino acid sequence of (a) or (b) above, or a retro-inverso peptide residue thereof; and n11 represents an integer of at least 0 but not more than 9.) [Formula 1] X11—(Y11—X12)n11  (I)

公开(公告)号：US20210163537A1

公开(公告)日：2021-06-03

申请号：US17044972

申请日：2019-04-25

申请人： NIIGATA UNIVERSITY

发明人： Eisaku KONDO ,  Ken SAITO

IPC分类号： C07K7/08 ,  C07K7/06 ,  A61K47/64 ,  A61P35/00 ,  A61K49/00

摘要： This peptide is composed of an amino acid sequence represented by general formula (I), and has a high degree of accumulation in cancer cells or cancer tissue in a digestive system. (In general formula (I), X11 is a peptide residue composed of an amino acid sequence of (a) or (b) below: (a) an amino acid sequence represented by any of SEQ ID NOs: 1 to 3, (b) an amino acid sequence including a sequence in which one or two amino acids have been deleted, substituted or added in an amino acid sequence represented by any of SEQ m NOs: 1 to 3; Y11 is a peptide linker composed of an amino acid residue of at least 1 but not more than 10 amino acids, wherein each amino acid residue is independently a glycine residue, a proline residue, a serine residue a cysteine residue or a lysine residue; X12 is either a peptide residue composed of an amino acid sequence of (a) or (b) above, or a retro-inverso peptide residue thereof; and n11 represents an integer of at least 1 but not more than 9.) [Formula 1] X11—(Y11—X12)n11  (I)